Vertex Pharmaceuticals Incorporated drugs
7 results
Alyftrek (vanzacaftor, tezacaftor, and deutivacaftor)
(vanzacaftor, tezacaftor, and deutivacaftor)Vertex Pharmaceuticals Incorporated
Usage: ALYFTREK is indicated for treating cystic fibrosis in patients aged 6 and older with at least one F508del mutation or another responsive CFTR mutation. An FDA-cleared CF mutation test is recommended if the patient's genotype is unknown.
Casgevy (exagamglogene autotemcel)
(exagamglogene autotemcel)Vertex Pharmaceuticals Incorporated
Usage: CASGEVY is indicated for treating patients aged 12 and older with sickle cell disease experiencing recurrent vaso-occlusive crises and those with transfusion-dependent β-thalassemia.
Journavx (suzetrigine)
(Suzetrigine)Vertex Pharmaceuticals Incorporated
Usage: JOURNAVX is indicated for treating moderate to severe acute pain in adults.
Kalydeco (ivacaftor)
(ivacaftor)Vertex Pharmaceuticals Incorporated
Usage: KALYDECO is indicated for treating cystic fibrosis in patients aged 1 month and older with at least one responsive CFTR gene mutation, supported by clinical or in vitro evidence. An FDA-cleared CF mutation test is recommended for patients with unknown genotypes.
Orkambi (lumacaftor and ivacaftor)
(lumacaftor and ivacaftor)Vertex Pharmaceuticals Incorporated
Usage: ORKAMBI is indicated for treating cystic fibrosis in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. Its efficacy and safety in patients without this specific mutation have not been established.
Symdeko (tezacaftor and ivacaftor)
(Tezacaftor and Ivacaftor)Vertex Pharmaceuticals Incorporated
Usage: SYMDEKO is indicated for treating cystic fibrosis in patients aged 6 and older who are homozygous for the F508del mutation or have a responsive CFTR gene mutation. Genetic testing is recommended to identify the appropriate mutations before treatment.
Trikafta (elexacaftor, tezacaftor, and ivacaftor)
(Elexacaftor, Tezacaftor, and Ivacaftor)Vertex Pharmaceuticals Incorporated
Usage: TRIKAFTA is indicated for treating cystic fibrosis in patients aged 2 years and older with at least one F508del mutation or another responsive CFTR gene mutation. If the genotype is unknown, an FDA-cleared CF mutation test is required to confirm the presence of an indicated mutation.